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Pseudoexfoliation syndrome (PXS) is a systemic condition with eye manifestations. In the eye, pseudoexfoliation
material deposits on various structures of the anterior segment. The nature of this material is mostly fibrillar with
fibers made up of microfibrils and coated with amorphous material. The composition of these fibrils is diverse and
includes basement membrane components as well as enzymes involved in extracellular matrix maintenance.
Pseudoexfoliation is the most common cause of secondary open-angle glaucoma (pseudoexfoliation glaucoma,
PXG) worldwide. The goal of this review is to summarize our knowledge on the genetics of this systemic disorder
and its resultant ocular manifestations. PXS familial aggregation suggests genetic inheritance. PXS has been strongly
associated with single nucleotide polymorphisms (SNPs) of the lysyl oxidase-like 1 (LOXL1) gene on chromosome
15q24.1. Two of these SNPs confer a higher than 99% population attributable risk for PXS and PXG in the Nordic
population; however, they carry different risks in different populations. The high risk haplotypes also vary among
different populations. LOXL1 is one of group of the enzymes involved in the cross-linking of collagen and elastin in
the extracellular matrix. Its function in connective tissue maintenance has been confirmed in mice; however, its
actual role in PXS remains unclear. Contactin-associated protein-like 2 also has a strong genetic association with
PXS in a German cohort and is an attractive candidate molecule. It encodes for a protein involved in potassium
channel trafficking. Other candidate genes linked to PXS include lysosomal trafficking regulator, clusterin, adenosine
receptors, matrix metalloproteinase-1 (MMP1), and glutathione transferase. These genes may be modifying genes
for development of PXS and PXG.
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Pseudoexfoliation syndrome (PXS) is a complex
systemic disorder of the extracellular matrix primarily
affecting the eye and visceral organs [1]. Pseudoexfo-
liation material (PXM) deposits around blood vessels
of connective tissue. It has been identified by electron
microscopy [2,3] and immunohistochemistry [4] in
the lung, liver, kidney, gall bladder, and cerebral
meninges. Cardio and cerebrovascular disease such as
angina, aortic aneurysm, and dementia have been
linked to PXS [5-7]; however, this association remains
controversial [8].* Correspondence: John.danias@downstate.edu
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In the eye, pseudoexfoliation syndrome is character-
ized by the deposition of fibrillar material that can be
found on all anterior segment structures bathed by
aqueous humor. PXM can be observed in vivo during
slit lamp examination. It appears as ‘dandruff-like’
material in the anterior chamber or most characteris-
tically on the anterior lens capsule deposited in a
double concentric ring pattern (Figure 1). The rings
are separated by a clear zone presumably created be-
cause of the movement of the iris on the anterior
lens surface. The central ring is located at the area of
the iris sphincter, while the peripheral ring is only
visible after pupil dilation. PXM is also often
observed by slit lamp examination at the pupillary
margin (Figure 2), on the lens zonules and on the
trabecular meshwork. The site of production of thisLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Anterior segment photography of the eye following
dilation of the pupil. Notice the deposition of PXM on the anterior
lens capsule. Arrows point to the characteristic double ring pattern.
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clear, but PXM can potentially originate from the iris, lens
epithelium, ciliary body, or the trabecular meshwork [1].
Ocular manifestations of PXS include iris depigmen-
tation leading to peripupillary transillumination defects,
mild trabecular meshwork hyperpigmenation, secondary
open-angle glaucoma, and phacodonesis or lens sublux-
ation caused by zonular dehiscence. Loss of lens zonular
support makes intraocular surgeries challenging with the
potential for vitreous loss, lens subluxation, or even lens
dislocation [9].
Although the ocular findings of PXS have been
described more than 80 years ago [10], the exact patho-
physiology of PXS is still obscure. Significant advances
in our understanding, however, have been made in re-
cent decades. This era of increased understanding startsFigure 2 Anterior segment photography of the eye showing
PXM deposition at the pupillary margin (arrows).with a hypothesis put forward by Barbara Streeten et al.
[3], who suggested that PXS is a form of elastosis result-
ing from the overproduction of elastic microfibrillar
components such as fibrillin-1 [11]. Further evidence
that fibrillin overproduction or over aggregation may be
causative for the formation of PXM came from the work
of Schlotzer et al. who detected an increased extracellu-
lar deposition of fibrillin-containing fibrils in PXS [12].
PXM pathology and nature
Transmission electron microscopy studies have con-
firmed that PXM is fibrillar in nature. Fibrils are com-
posed of microfibrils, each 8 to 10 nm in diameter that
undergoes lateral aggregation to produce complete PXM
fibrils [11]. The PXM fibrils also have a coating of
electron-dense amorphous material which often conceals
the microfibrillar nature [11].
Immunohistochemical findings have suggested that
PXM fibrils contain components of the elastic fiber and
basement membrane system, such as elastin, tropoelas-
tin, amyloid P, vitronectin, fibronectin, heparan sulfate
proteoglycan, fibrillin-1, microfibril-associated glycopro-
tein, emilin, and latent transforming growth factor β
binding proteins (LTBP-1 and LTBP-2) [11]. Liquid
chromatography coupled with tandem mass spectrom-
etry has confirmed the presence of fibrillin-1, fibulin-2,
vitronectin, and amyloid P-component. In addition, it
allowed the identification of the basement membrane
components laminin, serum amyloid protein and fibro-
nectin, desmosomal cadherins (desmocolin-2), the pro-
teoglycans syndecan-3, and versican metalloproteases of
the ‘A Disintegrin and Metalloprotease’ (ADAM) family
(ADAMTS-8, 18, and 19), tissue inhibitors of metallo-
protinases (TIMP3) the extracellular chaperone clus-
terin, and complement factor 1q (C1q) as components
of PXM microfibrils [13].
It is unclear whether PXM accumulates due to exces-
sive synthesis or inadequate breakdown. Elastic micro-
fibril components, such as fibrillin-1, as well as other
components of PXM such as LTBP-1 and LTBP-2 and
the enzyme transglutaminase 2 were found to be upre-
gulated at both the mRNA and protein levels in tissues
of the anterior segment of the eye, where PXM can often
be seen, suggesting excessive de novo synthesis as the
cause [14]. However, an observed [15-17] imbalance be-
tween matrix metalloproteinases (MMPs) and their tis-
sue inhibitors of metalloproteinases supports the
possibility of improper PXM degradation. It is likely that
PXM accumulation is a result of a combination of both
excessive synthesis and insufficient degradation.
Ocular complications of PXS
Pseudoexfoliation is the most common identifiable cause
of open-angle glaucoma (OAG) [1]. In the Blue
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lian population of European origin, patients with PXS in
either eye have a two to threefold higher risk of OAG,
while eyes with PXS had fivefold increased risk for OAG
even though OAG was often associated with only mod-
est increase in intraocular pressure. The eye-specific in
addition to patient-specific risk indicates the involve-
ment of PXM in the development of OAG [18]. Retinal
and optic nerve head pathology of pseudoexfoliation
glaucoma (PXG) is considered to be similar if not identi-
cal to that of primary open-angle glaucoma (POAG).
Axonal loss is seen in both; however, patients with PXG
seem to have smaller decrease in capillary density com-
pared with patients with POAG [19].
PXS demographics
Pseudoexfoliation syndrome is a late onset condition
with prevalence that increases markedly with age. In a
Finnish population, its prevalence reached 33% among
those aged 80 to 89 years. In Iceland the prevalence is
17.7% in patients aged 70 to 79 years and reached up to
40.6% in patients aged above 80 [20] years. PXS was also
found to be generally more prevalent in men than in
women [21]; this gender association though is not always
reproducible [20]. The incidence of PXS roughly doubles
each decade of life after the age of 50 [22] years. In Japan
the incidence of PXS increased with age from 0.7% in
ages 50 to 60 years to 7.3% in ages over 80 [22] years.
PXS as a potential genetic disease
The association between human leukocyte antigen
(HLA) and pseudoexfoliation suggests at least a genetic
component to the inheritance of pseudoexfoliation syn-
drome [23].
The inheritance nature, however, has been difficult to
determine because of late onset and the often asymp-
tomatic nature of the process. Aggregation of the disease
within families pointed to autosomal dominance inherit-
ance [18]. Other inheritance patterns such as X-linked
[24], maternal [25], and autosomal-recessive have also
been suggested [26].
PXS-associated genes and candidate molecules
Genome wide scan from one large pedigree suggested
18q12.1-21.33 as a promising locus. Other chromosomes
that showed positive linkage were chromosomes 2, 17,
and 19 but these overlapped with previously detected
loci for POAG [27].
Lysyl oxidase-like 1
A genome wide association study (GWAS) that was a
part of the decode group, which included 90 cases of
POAG, 75 cases of PXG, and 30 unclassified cases of
Icelandic background, detected a strong associationbetween PXG and a single nucleotide polymorphism
(SNP), rs2165241 [28]. The SNP lies in the first intron of
the lysyl oxidase-like 1 (LOXL1) gene on chromosome
15q24.1. The same group also pursued a confirmation of
this finding with a larger GWAS study of 594 subjects
affected with PXS or PXG and 14,672 controls from Ice-
land and Sweden. In the same chromosome, they uncov-
ered two new SNPs rs3825942 (G153D) and rs1048661
(R141L) in the first exon of the LOXL1 gene, conferring
a higher than 99% population attributable risk for PXS
and PXG [28].
The three haplotypes (G-G, G-A, and T-G), formed by
the alleles of the two nonsynonymous SNPs rs1048661
(R141L) and rs3825942 (G153D), carry different risks for
the conditions with G-G and T-G being the high risk
alleles while G-A being the low risk one [28]. T-A geno-
type was not observed in the study population.
Although the rs2165241 was more significantly asso-
ciated with PXG than the two exonic SNPs, this associ-
ation was no longer statistically significant after
adjusting for the other SNPs at the same time [28].
The SNP rs2165241 located in the first intron of
LOXL1 gene is strongly associated with PXG because it
tags the G-G high risk allele for the SNPs rs3825942 and
rs1048661 in the first exon of the LOXL1 gene [28].
In Iceland and Sweden the prevalence of the higher
risk haplotypes is 50%, and thus these haplotypes are
present in homozygous form in 25% of the general
population over the age of 50 years. The risk of patients
with this double homozygous genotype for developing
PXS and PXG is thus 700 times more than those with
only the lower risk haplotype [28].
The protein containing (Arg141-Gly153) is the one
associated with the highest risk for PXG in Nordic and
Caucasian populations. In contrast, the protein isoform
(Leu141-Gly153) carries the lowest risk for PXG. How-
ever, this finding has not been replicated in other popu-
lations. Only the G allele of rs3825942 (G153D) is
shown to carry high risk for PXS and PXG in both Cau-
casians and Japanese [29]. Although the high risk allele
of rs1048661 is the G allele in Caucasians and south
Indians [30], the T allele was the high risk allele in Japa-
nese and Chinese [31,32]. In a black South African
population, the G allele for rs1048661 (encoding argin-
ine) was the same risk allele to that of Caucasians, while
instead of the G allele the A allele of rs3825942 (encod-
ing aspartic acid) was the other high risk allele [33].
It thus appears that because of their high prevalence
in people without PXG in the Nordic population, the as-
sociation of rs1048661 and rs3825942 SNPs with PXG
may not be strong enough [34]. This difference in the
high risk alleles in various populations also suggests the
presence of other genes that contribute to the risk of
PXG [33].
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gene. LOXL1 is one of five enzymes in the family of lysyl
oxidases, which are copper-dependent monoamine oxi-
dases secreted by fibrogenic cells including fibroblasts
and smooth muscle cells. The members of this family in-
clude lysyl oxidase (LOX) and lysyl oxidase-like (LOXL)
1, 2, 3, and 4 [35]. These enzymes are involved in the co-
valent cross-linking of collagen and elastin polymers in
extracellular matrix formation. LOXL1 is necessary for
tropoelastin cross-linking and elastic fiber formation,
maintenance, and remodeling [36,37]. To accomplish
this, the LOXL1 pro-peptide binds to both tropoelastin
and fibulin-5 and selectively targets elastic microfibrils at
the sites of elastogenesis [37]. Fibrillins and microfibril-
associated glycoproteins are thought to form the scaffold
to align cross-linking domains of tropoelastin [38]. After
LOXL1 binds to the scaffolding, endo-metalloproteinase
procollagen C-terminal proteinase (bone morphogenetic
protein 1) cleaves the LOXL1 pro-peptide to prepare it
for activation [36]. By oxidatively deaminating the lysine
residues of tropoelastin, elastin fibers are covalently
cross-linked.
The product of the LOXL1 gene thus modifies elastin
fibers. The two single nucleotide polymorphism
rs1048661 and rs3825942 associated with PXS translate
into two different amino acids in the N-terminal of the
LOXL1 pro-peptide at positions 141 (Arg instead of
Leu) and 153 (Gly instead of Asp) [28].
Both coding SNPs in LOXL1 identified to date are in
exon 1, which is known to encode a unique N-terminal
domain of the LOXL1 proenzyme. Since this domain is
significant for the correct enzyme activation and sub-
strate recognition and binding, polymorphism in this re-
gion may affect enzyme function and subsequent PXM
production [39].
Defective LOXL1 function has been studied in LOXL1
knockout (KO) mice where it results in multiple con-
nective tissue defects. LOXL1 KO mice suffer from
emphysematous changes in the lungs and vascular ab-
normalities resulting from a failure of elastic fiber main-
tenance [37]. Though LOXL1-deficient mice are viable
and females are initially fertile, they undergo pelvic pro-
lapse 1 to 2 days postpartum. The mice also experience
increased laxity and redundancy of the skin, rectal pro-
lapse, and intestinal diverticula. LOXL1 KO mice are
prone to choroidal neovascularization after laser induc-
tion because of lack of elastic fiber maintenance in
Bruch’s membrane [40].
These findings confirm the importance of LOXL1 in
connective tissue maintenance. However, since PXM ac-
cumulation was not reported in these studies, it is un-
clear whether or not PXS occurs in LOXL1 KO mice.
Even if absent in these animals, it is possible that a par-
tial deficiency of LOXL1 may result in PXM formation,while complete loss of such activity may lead to minimal
PXM formation [40].
Lysosomal trafficking regulator
Animal studies have also suggested that the lysosomal
trafficking regulator (LYST) gene is potentially important
in PXS. LYST plays an important role in protein synthe-
sis responsible for lysosomal function. Mutation of the
LYST gene in human results in the lysosomal storage
disease, Chediak-Higashi syndrome, which is character-
ized by immune deficiency, neurological manifestations,
and bleeding tendency [41]. B6-Lystbg-J mice homozy-
gous for the beige-J (bg-J) allele show multiple ocular
features of human PXS [42]. Three key similarities were
the pattern of iris transillumination defects caused by an
unusual saw tooth-like morphology of the iris pigment
epithelium, the accumulation of material resembling
human PXM on the iris and elsewhere in the anterior
chamber, and pronounced iris pigment dispersion. The
beige mutation results from a 3-bp deletion causing the
loss of a single isoleucine from the WD40 domain of
the LYST protein, suggesting a disruption of protein-
protein interactions. Though the LYST mutant mice do
not resemble human PXS in all regards, they nonetheless
have the potential to serve as an animal model for PXS,
and may shed light on the complex genetic contribution
and molecular pathway of the disease [42].
Clusterin
Studies on clusterin have also indicated that its defi-
ciency may result in PXM accumulation. Clusterin
mRNA is expressed in most ocular cells and tissues, par-
ticularly in the epithelium of ciliary processes [14];
whereas the protein often localizes to extracellular struc-
tures, such as ocular basement membranes and stromal
fibers. The presence of clusterin was also documented in
the optic nerve and iris. In PXS eyes, a significant down
regulation of clusterin mRNA was seen in all anterior
segment tissues, irrespective of the presence of glau-
coma, when compared to normal eyes and eyes with pri-
mary open-angle glaucoma [14]. Clusterin aqueous
humor levels were also significantly reduced in PXS eyes
[14]. In vitro analysis of nonpigmented ciliary epithelial
cells has also shown significant down regulation of clus-
terin mRNA and protein upon exposure to transforming
growth factor β1 (TGF-β1). TGF-β1 has been found to
interact with lysyl oxidase in the formation of elastic
fibers and is upregulated in anterior segment tissues in
PXS (irrespective to the presence or absence of glau-
coma) as well as in eyes with POAG. In addition to its
interaction with clusterin and lysyl oxidase, TGF-β1 has
been known to regulate other multiple factors involved
in PXM accumulation, such as fibrillin-1, LTBP-1,
LTBP-2, tropoelastin, and transglutaminase-2 [43].
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and reduced amounts in aqueous humor of PXS eyes led
to an investigation of the genetic variants of the clusterin
(CLU) gene and its association with PXS. Nine SNPs
across the CLU gene in 86 cases of PXS and 2,422 con-
trols from the BMES cohort were genotyped. Variants of
CLU gene do not strongly modify the risk of PXS in the
Australian population, but one SNP (rs3087554) haplo-
type with 7% frequency may slightly increase the risk
[44]. Due to the small size of the cohort and the signifi-
cant age difference between cases and controls, the
power of this study was low. Further studies are needed
to verify any association [44].Adenosine receptor A3
Adenosine receptors are also candidate molecules. Ad-
enosine is known to regulate aqueous humor secretion
and affects intraocular pressure through its action on ad-
enosine receptors. Differential expression of mRNA of
adenosine receptors subtypes in PXS, PXG, and control
eyes has been detected [45]. A3 receptor mRNA and
protein were selectively upregulated and overexpressed
in the basolateral infoldings of nonpigmented epithelium
of the ciliary body in eyes with PXS with and without glau-
coma. In vitro, A3 receptors can be selectively upregulated
by hypoxia. PXS is characterized by anterior segment
hypoxia [11] and this hypoxia-induced overexpression of
adenosine receptors in PXS eyes not only indicates its
cytoprotective role but also potentially suggests a new
therapeutic option for PXS and PXG [45].Table 1 PXS-associated genes and associated
polymorphic markers
PXS associated gene Chromosome Associated
polymorphic
marker
LOXL1 gene [28,29,32-34,77-80] 15q24.1 rs2165241
rs3825942
rs1048661
Clusterin gene [14] 8p21 rs3087554
Glutathione transferase
gene [51,56,57]
1p13.3 M0 and T0
genotype
CNTNAP2 gene [58] 7q35 rs2107856
rs2141388




Blood group B [68] 9q34
*Reported frequencies are for the rs1048661 T allele which is the high risk
allele in the Japanese cohort.Homocysteine metabolism genes
Another factor that may be associated with PXG is
homocysteine. Increased plasma homocysteine level may
be a risk factor for the development of glaucoma [46]. In
a study of nonHispanic white population, plasma homo-
cysteine levels were found to be increased in both PXS
and PXG compared with controls [46]. Plasma homo-
cysteine level can be elevated because of many factors
such as genetic, folic acid deficiency, cobalamin defi-
ciency, slow metabolism as in hypothyroidism, lack of
excretion as in renal failure, and also aging. Methylene-
tetrahydrofolate reductase (MTHFR) controls homocyst-
eine concentration and the mutation in the MTHFR
gene can lead to reduced function and subsequent
homocystinemia. Thus, MTHFR is another candidate
gene [47]. The effects of polymorphisms in MTHFR and
four other genes that are involved in homocysteine me-
tabolism have thus been investigated. Those genes are
methionine synthase (MTR), methionine synthase reduc-
tase (MTRR), methylenetetrahydrofolate dehydrogenase
(MTHFD1), and cystathionine β-synthase (CBS). This
study that only involved subjects of Caucasian Europeanancestry, however, failed to show a relationship of homo-
cysteine levels with PXS or PXG and thus, homocys-
teine cannot be considered as a risk factor for PXS or
PXG [48].
Matrix metalloproteinases
Matrix metalloproteinases and their inhibitors are
known to play a role in extracellular matrix maintenance
and therefore may have an important role in PXS, either
promoting or limiting the progression of the disease
[3,49]. Based on studies of the genetic associations of
matrix metalloproteinase-1 and 3 (MMP1) and (MMP3)
gene polymorphisms with PXS in a Greek population, it
has been suggested that there is a possible role for
MMP1 variants in the development of PXS [49].
Glutathione transferase
Glutathione transferase (GST) plays an important role in
protecting cells from the oxidative damage caused by
oxygen-free radical formed inside the cells. It conjugates
those toxic products with glutathione, rendering them
water soluble and excretable by the body [50,51]. It is
found in the mitochondrial cytosole and lysosomes. The
cytosolic form has three classes; mu (μ), theta (θ), and pi
(π). The null genotype of mu is M0 and for theta is T0
[51]. Individuals carrying the null genotype have less
protection against oxidative damage. Polymorphisms of
GST have been detected in POAG [52], cataract [53],
and exudative age-related macular degeneration [54].
However, in patients with PXG of Turkish [55], Swedish
[56], and Arab [57] populations, no significant associ-
ation was noted. Recently, it was shown that the M0 and
T0 phenotype of GST is strongly associated with PXG in
female Pakistani patients [56].
Table 2 LOXL 1 SNPs high risk allele frequencies in different populations
Population Group Cohort
size





Iceland Control 14,474 0.847 0.651 [28]
PXS 55 0.982 10.10 (4.02 – 25.36) 8.5 × 10−7 0.789 2.02 (1.32 – 3.09) 1.3 × 10−3
PXG 75 0.987 13.23 (5.59 – 31.29) 4. × 10−9 0.827 2.56 (1.74 – 3.77) 1.8 × 10−6
Sweden Control 198 0.879 68 [28]
PXS NA NA NA
PXG 199 0.995 27.28 (11.44 – 65.07) 9.1 × 10−14 0.834 2.39 (1.72 – 3.34) 2.7 × 10−7
USA Control 235 0.844 0.665 [34]
PXS NA NA
PXG 50 0.939 3.05(1.20 – 7.76) 0.0194 0.787 1.86(1.10, 3.15) 0.0222
India Control 97 0.74 0.63 [30]
PXS and
PXG
52 0.92 0.0001 0.72 0.156
Japan Control 172 0.863 0.503*
PXS 103 0.985 10.71 (3.29 – 34.87) 1.49 *10−7 0.932* 13.56 (7.57 – 24.27) 3.39 *10−28 [29]
PXG 106 0.986 11.02 (3.39 – 35.9) 1.40 *10−7 0.962* 25.21 (12.06 – 52.69) 1.44* 10−34
Chinese Control 171 0.918 0.444
PXS and
PXG
62 0.992 1.92 (1.25 – 2.96) 0.0034 0.524 1.92 (1.25 – 2.96) 0.0034 [77]
German Control 348 0.857 0.644
PXS 206 0.948 3.06 (1.87 – 4.99) 3.15 *10−6 0.787 2.04 (1.54 – 2.71) 7.08 * 10−7 [78]
PXG 311 0.953 3.41 (2.22 – 5.24) 4.78 *10−9 0.839 2.89 (2.21 – 3.77) 1.40 *10−15
Italian Control 70 0.821 0.693
PXS 76 1.000 ∞ 5.08 *10−8 0.842 2.36 (1.34 – 4.16) 0.0024 [78]
PXG 133 1.000 ∞ 1.96 *10−12 0.815 1.96 (1.22 – 3.15) 0.0053
Australian Control 86 0.84 0.66
PXS 335 0.95 3.81 (1.88 – 9.02) 7.83*10−5 0.78 1.86 (1.27 – 2.76) 8.49*10−4 [79]
PXG NA NA
Saudi Control 101 0.817 0.762 [80]
PXS NA NA NA
PXG 93 0.968 0.000005 0.876 0.0056
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A genome wide association study with DNA pooling also
linked variants of contactin-associated protein-like 2
(CNTNAP2) gene on chromosome 7 (also known as
Caspr2) to PXS [58]. Little information is available about
the function of this protein. CNTNAP2 is a transmem-
brane scaffolding protein involved in the clustering of
potassium voltage-gated channel subfamily A (Kv1.1)
[59]. It is believed to regulate potassium channels at
neuron membranes and may have a role in membrane
stabilization [60]. This gene has been implicated in
several neuropsychiatric disorders [58]. To replicate the
association findings, these SNPs were genotyped in an
independent German cohort of 610 subjects withpseudoexfoliation syndrome/pseudoexfoliation glaucoma
PEX/PXG and 364 controls as well as in 249 Italian
subjects and 190 controls. A detailed analysis of this
locus confirmed the association between two SNPs
(rs2107856, rs2141388) and PXS/PXG in the German,
but not in the Italian cohort. It also confirmed the two
SNPs reported for the LOXL1 gene and detected an as-
sociation of CNTNAP2 with the T (non-risk) haplotype
of LOXL1 gene [58].
CNTNAP2 mRNA and protein distribution in ocular
tissues were studied using real time polymerase chain re-
action and immunohistochemistry. CNTNAP2 localizes
to epithelial and endothelial cells including the trabecu-
lar meshwork, Schlemm’s canal, cornea, nonpigmented
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and optic nerve. The labeling of cell membranes is
reduced in PXS and PXG patients [58].Tumor necrosis factor alpha gene polymorphism G-308A
Tumor necrosis factor (TNF)-α is a proinflamatory cyto-
kine that has been implicated in various neurodegenera-
tive disorders including glaucoma [61].
It is presumed to have dual roles depending on which
receptor is activated. The activation of high affinity
TNF-R2 receptor is thought to be neuroprotective, while
activation of the low affinity TNF-R1 receptors mediates
cell death through mitochondrial apoptosis [62]. An
increased expression of TNF-α can shift the balance and
stimulate TNF-R1 receptors [62].
TNF-α and its receptor (TNF-R1) m RNA were
increased in the retina of glaucoma patients [63], while
anti TNF-α antibodies can prevent ganglion cell death in
a mouse model of glaucoma [64].
One SNP (G-308A of rs1800629) upstream of the pro-
moter site of TNF-α activates the expression and causes
elevation of TNF-α [62]. The association of this SNP
with PXS has been recently studied in various popula-
tions. A strong association of GA and AA genotypes was
observed with PXG in the Pakistani and Iranian popula-
tions [62,65]. However, this association was not con-
firmed in the Turkish [66] or Caucasian population [67].Table 3 Molecules related to PXS, function, and nature of ass
Molecules related to PXS Known function
Lysyl oxidase-like 1 (LOXL1)
[28,32,34,78]
Copper-dependent monoamine
secreted by fibrogenic cells. Cata
covalent cross-linking of collage
elastin in ECM formation
Clusterin [14] Clearance of cellular debris and
Homocysteine and human cell
metabolic enzymes (MTHFR MTR,
MTRR, MTHFD1, CBS) [46,47]
Amino acids that participate in m
metabolic processes.
Glutathione transferase [50,51,56,57] It conjugates those toxic produc
glutathione, protecting cells from
oxidative damage
CNTNAP2 (Caspr 2) [58,60] Regulation of potassium channe
neuron membranes. Possible rol
membrane stabilization
MMPs (MMP1) [15-17,49] Extracellular matrix maintenance
Adenosine receptors [45] Adenosine regulates aqueous hu
secretion. Intraocular pressure ar
regulated through adenosine re
TNF-α [65] Has dual action depending on t
type of receptor activated.
High affinity TNF-R2 receptor ha
neuroprotective function while l
affinity TNF-R1 receptors activati
leads to cell death.ABO blood groups
The association between blood groups and different
glaucoma types was assessed in various case control and
cross-sectional studies. A strong association between
blood group type B and different types of glaucoma in-
cluding PXG was found in Pakistani and Iranian popula-
tions [68,69]. The significance of this association is not
clear at this time.Gene-environment interactions
Although familial aggregation, HLA and polymorphic
marker association and geographical clustering suggest a
genetic nature of PXS; environmental factors have been
also suggested to play a role in the natural history of the
disease [70].
The effect of ultraviolet (UV) light has been investi-
gated, as PXS is more prevalent in populations with rela-
tively high UV exposure [70,71].
Other environmental factors that have been proposed
to participate in the pathogenesis of PXS are slow virus
infection [72] and autoimmunity [73]. The report of the
occurrence of PXS in relatively young patients after
keratoplasty suggests the transmission of the disease
from donor to the recipient. However, this cannot be
considered proof, as development of PXS can also be the
result of trauma or endothelial cell proliferation in the
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http://www.humgenomics.com/content/6/1/22patients developing PXS after cataract surgery suggest
that anterior segment trauma may be a predisposing fac-
tor in PXS development [75,76].
Summary
Pseudoexfoliation syndrome is the systemic disorder
with characteristic eye manifestations. It is the cause of
one of the secondary open-angle glaucomas. Evidence
suggests a strong genetic component to this condition
(Table 1). To date a number of genes have been linked
to PXS, of which LOXL1 appears to be the most relevant
in many populations (Table 2). Recently, GST and
CTNTAP2 genes were also found to be highly associated
in some populations. Other candidate genes such as ad-
enosine and clusterin, TNF-α, blood group type B show
weaker associations but may contribute to the phenotype
as modifying genes (Table 3).
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